Home | About Us | Grants | Resources | News & Events | Community

Vision: We may not be there yet, but we are closer than we were yesterday.
Link to Donation Page


About Us
arrowHistory & Background

arrowGrant Opportunities
arrowGrant Process
arrowASN Co-Grants
arrow2015 Grant Recipient
2013 Grant Recipient
Translational Research

arrowPatient Registries
arrowMedical Experts
arrowBio Banks

News & Events
arrow2018 MN Conference in Bergamo
HFE Gene Linked to MN
arrowCureGN Study at Columbia
Protein Linked to Kidney Failure
arrowNIH Renews NEPTUNE Funding
Childhood Stress not trigger for MS
arrowLevin succeeds Remuzzi at ISN

arrowSalant receives Hamburger Award
arrowDrug for MS & Alzheimer's
arrowNeurons & Salt
arrowAutoimmune-Allergy Connection
arrowA Cause of Recurrent MN
arrowBlood Test Detects Kidney Rejection
Genotyping of Risk Alleles
arrowLink to Gene Variants

arrowBlood Test to Detect MN
arrowMN, an Autoimmune Disease
arrowKey Molecule Impacts Mice
arrowLa Jolla Institute
arrowGluten Specific T-cells
arrowHuman Gene Pool
arrowVitamin D & Clinical Outcomes
arrowBovine Serum Albumen
Variations in HLA-DQA1 & PLA2R1 regions
arrowKlotho and Kidney Disease
arrowLink between MN and Milk (NEJM)

arrowASN News Release
arrowMario Negri News Release

arrowHyper-IgG4 Syndrome News Release
arrowAdvances in Kidney Disease (RSS)
arrowKidney Disease News (RSS)
arrowNew Patents (RSS)
arrowScience Daily (RSS)
arrowUpcoming Events
arrowEvents Archive

arrowPublic Service Announcement


CureGN Observational Study
at Columbia University

CureGN is an NIH-sponsored observational study on glomerular diseases which will include 600 patients with membranous nephropathy. The goals of this study are to advance the science behind our understanding of these diseases We hope to answer some of the most common questions patients have for their nephrologists:

• What is this disease?
• Why do I have this disease?
• What will happen to me?
• What effective treatments can you offer me?

Patients with recently diagnosed membranous nephropathy (a biopsy within the past 5 years) are eligible to participate in this important study. They will be asked to come to a study center once or twice a year, contribute blood and urine specimens for banking in a national biorepository, and answer questionnaires about their disease course.

Participation does not affect the way patients are treated, and there are no experimental treatments involved. Patients will meet with a study coordinator and study physician at these visits. To defray the costs of transportation, patients will be given $25 at each visit.

Interested patients should directly contact:
• Maddalena Marasa mm4440@cumc.columbia.edu or
• Michael DiVecchia md3292@cumc.columbia.edu

These are the lead study coordinators at Columbia University Medical Center.

Andrew Bomback, MD, MPH
Columbia University
Medical Center Division of Nephrology
622 West 168th Street, PH 4-124
New York, NY 10032
212-305-0320 (phone)
212-342-1814 (fax)